Cargando…

Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel

Pancreatic cancer is a dismal disease with a mortality rate almost similar to its incidence rate. To date, there are neither validated predictive nor prognostic biomarkers for this lethal disease. Thus, the aim of the present study was to retrospectively investigate the capability of biochemical par...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bianconi, Daniela, Heller, Gerwin, Spies, Daniel, Herac, Merima, Gleiss, Andreas, Liebmann-Reindl, Sandra, Unseld, Matthias, Kieler, Markus, Scheithauer, Werner, Streubel, Berthold, Zielinski, Christoph C., Prager, Gerald W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501799/ https://www.ncbi.nlm.nih.gov/pubmed/28687745 http://dx.doi.org/10.1038/s41598-017-04743-0

Ejemplares similares

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
por: Bianconi, Daniela, et al.
Publicado: (2020)

Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing
por: Balendran-Braun, Sukirthini, et al.
Publicado: (2021)

SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment
por: Bianconi, Daniela, et al.
Publicado: (2018)

Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior
por: Bianconi, Daniela, et al.
Publicado: (2022)

A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid
por: Kieler, Markus, et al.
Publicado: (2019)

Interactions of EGFR/PTEN/mTOR-Pathway Activation and Estrogen Receptor Expression in Cervical Cancer
por: Bartl, Thomas, et al.
Publicado: (2023)

Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
por: Kieler, Markus, et al.
Publicado: (2020)

Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
por: Kieler, Markus, et al.
Publicado: (2017)

Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
por: Kieler, Markus, et al.
Publicado: (2018)

Genetic diagnosis and clinical evaluation of severe fetal akinesia syndrome
por: Reischer, Theresa, et al.
Publicado: (2020)

nab-Paclitaxel for the treatment of pancreatic cancer
por: Kim, George
Publicado: (2017)

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
por: Kokubu, Hiraku, et al.
Publicado: (2023)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
por: Wan, Rui, et al.
Publicado: (2023)

Integrins in the Spotlight of Cancer
por: Bianconi, Daniela, et al.
Publicado: (2016)

Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma
por: Reni, Michele, et al.
Publicado: (2016)

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel()
por: de Leon, Maria C.B., et al.
Publicado: (2013)

nab-Paclitaxel dose and schedule in breast cancer
por: Martín, Miguel
Publicado: (2015)

Neoadjuvant nab-paclitaxel in the treatment of breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2016)

Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT
por: Unseld, Matthias, et al.
Publicado: (2018)

Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease
por: Kieler, Markus, et al.
Publicado: (2016)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab−Paclitaxel and Maintenance Monotherapy with nab−Paclitaxel: Two Case Reports
por: Araya, Tomoyuki, et al.
Publicado: (2020)

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial
por: Tabernero, Josep, et al.
Publicado: (2017)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
por: Funaishi, Kunihiko, et al.
Publicado: (2017)

Genetic association in female stress urinary incontinence based on proteomic findings: a case-control study
por: Reischer, Theresa, et al.
Publicado: (2019)

Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
por: Al-Hajeili, Marwan, et al.
Publicado: (2014)

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
por: Alvarez, R, et al.
Publicado: (2013)

A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion
por: Singh, Harjinder, et al.
Publicado: (2023)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020)

Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients
por: Unseld, Matthias, et al.
Publicado: (2020)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023)

Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayeasian network meta-analysis
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2021)

Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2021)

Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
por: Yamamoto, Yutaka, et al.
Publicado: (2011)

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer
por: Vishnu, Prakash, et al.
Publicado: (2011)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
por: De Luca, Rossella, et al.
Publicado: (2018)

Nab-paclitaxel - Third-line chemotherapy in advanced gallbladder cancer
por: Patel, Amol, et al.
Publicado: (2020)

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
por: Chen, Nianhang, et al.
Publicado: (2015)

Molecular pathology of cancer: how to communicate with disease
por: Birner, Peter, et al.
Publicado: (2016)

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
por: Schokker, Sandor, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0tvr9jca8id222j4lhq129pg26